The double-edged sword of modern cancer immunotherapy
In short: Immune checkpoint inhibitors have transformed cancer survival rates, but they come with a hidden neurological cost. While these therapies empower the immune system to hunt tumors, they can inadvertently trigger rare, severe attacks on the nervous system, creating a delicate biological balancing act for oncologists.
Immune checkpoint inhibitors (ICIs) have revolutionized oncology by significantly improving patient survival rates. However, as their clinical use increases, researchers are closely monitoring neurological adverse events. A systematic review and meta-analysis of 31 clinical trials, involving 8,826 cancer patients, provides a clearer picture of these risks. Data for this study were gathered from Embase, PubMed, Scopus, and the Cochrane Central Register of Controlled Trials. The analysis focused specifically on patients who had not previously undergone any systemic therapy.
The study found that the pooled incidence of neurological adverse events is quite low, estimated at approximately 1 in 5,000 patients (1.78 × 10⁻³%). Interestingly, the data suggests that using two ICIs instead of one does not significantly increase this specific risk, with incidence rates of 0.90 × 10⁻³% for dual therapy compared to 1.83 × 10⁻³% for single therapy.
The most frequent neurological complications identified include peripheral neuropathy, affecting about 1.34 in 100,000 patients, followed by myositis, aseptic meningitis, and autoimmune demyelinating polyneuropathy. Other rare occurrences include epilepsy and myasthenia gravis, both appearing in roughly 0.66 in 100,000 patients. While these events are infrequent, they highlight the complexity of modulating the immune system to fight malignancies like non-small cell lung carcinoma or melanoma without causing unintended neurological damage. The study noted no significant difference in these risks between patients with melanoma and those with hepatocellular carcinoma. Furthermore, the incidence rates remained comparable for individuals diagnosed with non-small cell lung carcinoma.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: The neurological adverse events of immune check point inhibitors in the treatment of cancer.
- Also: Check Point
To cite this card, link to https://intellectplus.co.uk/app/health-check-point.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Future Frontier · More in Health · Latest · A–Z · All topics
